Search

everythinglearnresearchcommunity

for

Search:↓

Low-dose oral minoxidil is a safe and effective hair loss treatment with fewer side effects than previously feared. Users often prefer it over topical minoxidil for better results, though some experience side effects like increased body hair and cardiovascular issues.

The conversation humorously discusses an extensive and exaggerated hair loss treatment regimen, including finasteride, dutasteride, minoxidil, pyrilutamide, RU58841, and various other therapies. Despite the numerous treatments, the effectiveness is questioned, and the user humorously considers adding more minoxidil.

The conversation discusses using 2-deoxy-d-ribose (2DDR) for hair regrowth, with users sharing mixed experiences and side effects like hair loss in new areas and increased anxiety. The original poster plans to continue testing and comparing it to minoxidil, noting potential instability in 2DDR formulations.

A 30-year-old man experienced significant hair loss after starting testosterone replacement therapy (TRT), which did not improve with daily finasteride and minoxidil. He is considering restarting TRT and is seeking advice on using pyrilutamide or RU58841 to prevent further hair loss.

The conversation discusses whether creatine causes hair loss for those using finasteride or dutasteride, with some suggesting creatine might increase DHT or upregulate androgen receptors, potentially leading to hair loss. Others argue the evidence is not conclusive, citing limited studies and personal anecdotes, with some avoiding creatine as a precaution.

The potential of verteporfin to heal wounds without scarring; however, despite its promising preclinical trials and coverage from a major media outlet, there is still no official clinical trial result and the drug has only garnered attention from hair loss communities.

This conversation is about how topical treatments for hair loss, such as Minoxidil and Finasteride, can be replaced by drinking oral versions of the same medications to achieve better results with less hassle. Some users have already been doing this with positive results.

Sulforaphane shows potential for hair regrowth, with users reporting reduced shedding and regrowth. Some users combine it with Minoxidil and finasteride for better results.

The conversation discusses the potential of topical rapamycin, metformin, and alpha-ketoglutarate (a-KG) for hair growth, with skepticism expressed about their effectiveness based on personal experience and existing use. It also mentions AICAR, known as cardarine or GW, which is not suitable for long-term use due to cancer risks in animal studies and its similarity to metformin.

PP405 is the most promising future treatment for hair loss, aiming to reactivate dormant hair follicles. Clascoterone 5% is the most promising near-term drug, while current strategies include using finasteride or dutasteride to stabilize hair loss and minoxidil to stimulate growth.

Hair growth caps and helmets using low-level laser therapy (LLLT) show potential for treating androgenetic alopecia, but more research is needed. Users often combine these devices with treatments like minoxidil and finasteride for better results.

People are hopeful for a permanent hair loss solution by the 2030s, considering options like hair cloning and treatments like pp405. Synthetic hair transplants have been attempted but are not effective long-term.

PP405 is a promising new hair loss treatment that may reactivate dormant hair follicles without side effects. It could surpass traditional treatments like minoxidil and finasteride if successful in further trials.

P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.

KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.

Minoxidil is more effective when combined with retinoic acid, such as tretinoin or tazarotene, enhancing hair growth. Some users experience significant regrowth, while others see minimal effects or side effects.

ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.

Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.

The conversation discusses a claim that peppermint oil is more effective than minoxidil for hair loss, with one user mentioning using a mix of peppermint and rosemary oils as a treatment. Some users are skeptical, while others show interest in the potential of peppermint oil.

The user tried Minoxidil without success, and Finasteride worked but caused sexual side effects even at a very low dose. They are seeking alternative treatments for hair loss as they cannot tolerate anti-androgens and are also in therapy for mental health.

User discusses potential hair loss treatment SCUBE3 and shares mixed opinions on its effectiveness. One user reports positive results after applying SCUBE3 following microneedling.

Researchers at the University of Virginia discovered a new group of stem cells in hair follicles that could potentially restore hair growth. The findings suggest that activating these stem cells might offer a new way to combat hair loss, though practical treatments are still years away.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

A 26-year-old is considering embracing baldness after mixed results and side effects from using dutasteride, minoxidil, and finasteride for hair loss. Suggestions include trying new hairstyles, considering a hair transplant, or focusing on self-acceptance.

The user reported noticeable hair thickening after 10 days of using oral minoxidil and finasteride, but others suggested it might be an April Fool's joke or a placebo effect. The user also mentioned a high protein intake and regular gym workouts, while others discussed concerns about finasteride's side effects.

The conversation critiques the influence of "Clavicular" on young men regarding hair loss treatments, highlighting the dangers of following unscientific advice and the rise of body dysmorphia. It emphasizes the importance of safe, medically advised treatments like minoxidil, finasteride, and dutasteride, while warning against reckless experimentation and early surgeries.

The user saw no significant changes in hair loss after three months on 3mg Dutasteride, having previously used Finasteride and 0.5mg Dutasteride. They plan to continue the high dose for a year despite concerns about side effects and diminishing returns.

Clascoterone 5% and PP405 are being discussed as potential future treatments for hair loss, with clascoterone nearing phase three completion and PP405 possibly taking a cosmetic route to market. Current treatments like minoxidil, finasteride, and RU58841 are mentioned as effective in slowing hair loss, but a complete cure remains elusive.

Hair growth relies on mechanical forces, not just chemicals, with tissue acting like a motor. Minoxidil and finasteride help, but maintaining tissue elasticity and addressing mechanical issues are essential.

PP405 is considered as a potential hair regrowth treatment, but users are skeptical due to past product failures. They compare it to Minoxidil and Finasteride, questioning its effectiveness and the intentions of pharmaceutical companies.